Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-9242 D2 Receptor Occupancy PET Study
NCT02824666Phase 1Completed
- Sponsor
- Braeburn Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ATI-9242 in schizophrenia (2 arms), sponsored by Braeburn Pharmaceuticals. Primary endpoint: Target receptor occupancy at 5 weeks. Started Jun 2016; status: completed.
02
Drugs
ATI-9242
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02824666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02824666.